Oruka Therapeutics
ORKA · Nasdaq · United States
Share price · ORKA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ORKA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+4.7%
Nothing announced by ORKA that day or the session before.
- 26 Oct 2026+12.7%
- 15 Oct 2026-3.7%
Nothing announced by ORKA that day or the session before.
- 30 Jul 2026+11.1%
Nothing announced by ORKA that day or the session before.
- 17 Jul 2026+11.6%
Nothing announced by ORKA that day or the session before.
- 2 Jul 2026-8.7%
Nothing announced by ORKA that day or the session before.
- 22 Jun 2026+18.0%
Nothing announced by ORKA that day or the session before.
- 27 Apr 2026+10.7%
- 13 Mar 2026+25.0%
Nothing announced by ORKA that day or the session before.
- 12 Jan 2026+10.2%
Nothing announced by ORKA that day or the session before.
Share of unusual movement by asset
For each asset, the share of ORKA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | IL-23 p19Monoclonal antibody | Psoriasis | |
| Phase 2 | IL-17A/FMonoclonal antibody | PsoriasisHidradenitis Suppurativa |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2028 (1)
2029 (1)
2030 (1)
May 2030 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (19)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $54M | $192M+ $729M short-term inv. | $50M-$44M operating cash flow | report ↗ |
View 18 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $43M | $268M+ $605M short-term inv. | $41M-$33M operating cash flow | report ↗ |
| 2026-Q1 | — | $29M | $50M+ $339M short-term inv. | $32M-$24M operating cash flow | report ↗ |
| 2025-Q3 | — | $29M | $91M+ $258M short-term inv. | $30M-$22M operating cash flow | report ↗ |
| 2025-Q2 | — | $24M | $65M+ $263M short-term inv. | $25M-$23M operating cash flow | report ↗ |
| 2025-Q1 | — | $20M | $84M+ $266M short-term inv. | $21M-$21M operating cash flow | report ↗ |
| 2024-Q3 | — | $26M | $411M | $29M-$28M operating cash flow | report ↗ |
| 2024-Q2 | — | $0.1M | $33M | $2.7M-$2.6M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $0.2M | $36M | $2.0M-$1.5M operating cash flow | report ↗ |
| 2023-Q4 | — | — | $37M | $1.1M-$1.1M operating cash flow | report ↗ |
| 2023-Q3 | — | $0.3M | $38M | $1.4M-$1.7M operating cash flow | report ↗ |
| 2023-Q2 | — | $0.3M | $40M | $1.5M-$0.7M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $0.4M | $41M | $1.4M-$1.6M operating cash flow | report ↗ |
| 2022-Q4 | — | — | $42M | $1.2M-$1.5M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.0M | $44M | $2.3M-$2.5M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.5M | $46M | $3.1M-$2.6M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $2.2M | $49M | $3.3M-$4.3M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $53M | $5.7M-$5.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.4M | $58M | $4.7M-$4.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $101M | $47M+ $290M short-term inv. | $26M-$88M operating cash flow | report ↗ |
For fiscal year 2025, Oruka Therapeutics reported no disclosed revenue, R&D spend of $100.64M, cash and equivalents of $46.94M, and a net loss of $105.43M. The company’s quarterly net burn was $105.43M.
Oruka is advancing clinical-stage antibody programs for inflammatory diseases. ORKA-001, targeting IL-23p19, showed Phase 1 interim results with a human half-life of approximately 100 days and sustained STAT3 inhibition through 24 weeks; the Phase 2a EVERLAST-A trial is expected to report Week 16 data in the second quarter of 2026, and the Phase 2b EVERLAST-B trial, with first patients dosed in December 2025, has data anticipated in 2027. ORKA-002, targeting IL-17A/F, showed a Phase 1 interim half-life of approximately 75-80 days, and the Phase 2 ORCA-SURGE trial was initiated in February 2026 with data anticipated in 2027, alongside a planned Phase 2 trial in hidradenitis suppurativa in the second half of 2026. No financial guidance was provided.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 145 sales ($343.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Option exercise | 3,500 | $6.84 | $24K | Form 4 |
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Option exercise | 3,500 | $7.80 | $27K | Form 4 |
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Open-market sale | 2,600 | $99.52 | $259K | Form 4 |
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Open-market sale | 1,500 | $100.48 | $151K | Form 4 |
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Open-market sale | 1,900 | $101.53 | $193K | Form 4 |
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Open-market sale | 300 | $102.47 | $31K | Form 4 |
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Open-market sale | 200 | $103.36 | $21K | Form 4 |
| 2026-11-16 | Goncalves Joana · Chief Medical Officer | Open-market sale | 500 | $105.86 | $53K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 184 reporting institutions held 52.9M shares ($2.6B, 78.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 7,431,403 | $364.5M |
| 2 | Venrock Adviser, LLC | 4,148,428 | $203.5M |
| 3 | Fairmount Funds Management LLC | 3,705,262 | $181.7M |
| 4 | BlackRock, Inc. | 3,527,087 | $173.0M |
| 5 | VIKING GLOBAL INVESTORS LP | 2,666,690 | $130.8M |
| 6 | Paradigm Biocapital Advisors LP | 2,320,316 | $113.8M |
| 7 | RTW INVESTMENTS, LP | 2,058,148 | $101.0M |
| 8 | Deep Track Capital, LP | 2,034,203 | $99.8M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 1,859,631 | $91.2M |
| 10 | Avidity Partners Management LP | 1,520,848 | $89.3M |
| 11 | STATE STREET CORP | 1,613,461 | $79.1M |
| 12 | Remedium Capital Partners, LLC | 1,565,661 | $76.8M |
| 13 | PERCEPTIVE ADVISORS LLC | 1,395,501 | $68.4M |
| 14 | Polar Capital Holdings Plc | 1,047,693 | $51.4M |
| 15 | CITADEL ADVISORS LLC | 1,007,537 | $49.4M |